The most frequent adverse events of any grade that were of special interest with durvalumab versus placebo were diarrhea (18.3% and 18.8%), pneumonitis (12.6% and 7.7%), rash (12.2% and 7.3%), and ...

Imfinzi (durvalumab) is a prescription drug used to treat certain types of cancer. Imfinzi can cause side effects that range from mild to serious. Examples include fatigue, rash, nausea ...

The most common all-grade AEs were rash (8 percent), diarrhea (7 percent), pruritus (4 percent), hyperthyroidism (4 percent) and hypothyroidism (4 percent). There are currently seven phase 3 studies ...

rash, and diarrhea The newest data do not show new safety signals emerging in the neoadjuvant or adjuvant setting, and that durvalumab plus neoadjuvant chemotherapy had a safety profile consistent ...

The most common (≥ 20%) adverse reactions were fatigue, nausea, constipation, decreased appetite, abdominal pain, rash, and pyrexia. The agency noted that the recommended durvalumab dosage is ...

From efficacy data for durvalumab monotherapy in pre-treated ... were fatigue (18%), diarrhoea and nausea (8% each), pruritus, rash and maculopapular rash (7% each). 5 Five patients (8% ...